A groundbreaking development in the fight against sleeping sickness, a deadly disease prevalent in Africa, has emerged with the approval of a single-dose oral treatment. This milestone achievement offers hope for a future free from this neglected yet devastating illness.
The European Medicines Agency's recent decision to approve acoziborole Winthrop, a one-day oral therapy, marks a significant advancement in the treatment of human African trypanosomiasis. This approval covers a wide range of patients, including adults and adolescents, and targets both early and advanced stages of the disease.
What makes this particularly interesting is the regulatory pathway taken. The EU-M4all pathway, reserved for high-priority medicines, highlights the urgency and importance of addressing diseases with unmet medical needs. This approval not only paves the way for further adoption in the Democratic Republic of Congo (DRC) but also signals a potential revision of WHO treatment guidelines, improving access to this life-saving treatment across affected regions.
The development of acoziborole is a collaborative effort between the Drugs for Neglected Diseases initiative (DNDi) and Sanofi, and it represents a major leap forward from existing treatments. The new drug offers a simpler and safer alternative to the previous 10-day oral regimens or combination injections, making it more accessible and patient-friendly.
Dr Luis Pizarro, executive director at DNDi, emphasizes the transformative nature of this progress, stating that it brings us closer to eliminating sleeping sickness, a disease that has claimed millions of lives on the African continent. This breakthrough is a testament to the power of collaborative science and innovation in tackling neglected diseases.
For Kenya, this approval holds special significance. The country has been validated by WHO as having eliminated human African trypanosomiasis as a public health problem, joining a select group of ten nations that have achieved this milestone. Kenya's success in combating this disease is a remarkable achievement and a model for other countries.
The strain of sleeping sickness found in Kenya, rhodesiense, is known for its rapid progression and fatal consequences if left untreated. The new drug, however, targets the gambiense form, which is more prevalent globally, accounting for over 94% of cases. This targeted approach is crucial in effectively eliminating the disease.
Human African trypanosomiasis is a deadly disease transmitted through the bite of infected tsetse flies. Without treatment, it is almost always fatal. In its early stages, patients experience headaches and fever, but as it advances, the parasite attacks the central nervous system, leading to seizures, confusion, and ultimately death. The success rates of acoziborole, up to 96% across both disease stages, as demonstrated in clinical trials in the DRC and Guinea, are a testament to its effectiveness.
Dr Erick Miaka, director of the DRC's national sleeping sickness control program, emphasizes the role of African-led science in this achievement. The development of acoziborole was made possible by the dedication and expertise of African doctors and researchers working in challenging environments.
Historically, sleeping sickness has been a significant public health concern, with nearly 40,000 cases reported globally in 1998. However, breakthroughs in combination therapy and the introduction of oral treatments have led to a dramatic decline, with fewer than 600 cases reported by 2024. Sanofi's commitment to donate acoziborole to WHO through its philanthropic arm ensures that this life-saving treatment will be accessible free of charge, further contributing to the global effort to eliminate sleeping sickness.
